Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regulators about the design of a ...

The global retinitis pigmentosa market size was valued at USD 14.02 billion in 2023 and is predicted to hit around USD 19.90 billion by 2032, a study published by Towards Healthcare a sister firm of ...

An estimated 1.5 million people worldwide live with retinitis pigmentosa, which starts with loss of night vision and usually ...

Significant advances have been made in the understanding of the genetics of retinitis pigmentosa (RP), a clinically and genetically heterogeneous group of disorders; and over 50 genes underlying ...

Several companies are experimenting with optogenetics to create a “bionic eye” that can restore sight in visually impaired ...

A quartet of studies presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting addressed ...

Researchers identify a protein crucial for breaking down misfolded proteins, a target for treating degenerative conditions ...

There are still many enigmas about the mechanism of action of the CERKL gene, which causes retinitis pigmentosa and other hereditary vision diseases. A team of scientists from the University of ...

Gene therapy demonstrated clinically meaningful vision improvement in legally blind individuals. The therapy is capable of ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, announced that Dr. Benjamin Bakall will present ...